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S U M M A R Y
We observed two cases of Clostridium tertium bacteremia three months apart in the sterile unit of our
department of hematology and oncology. One patient was being treated for ﬁrst-relapse acute
myeloblastic leukemia, while the second was receiving high-dose chemotherapy with hematopoietic
stem cell support for non-Hodgkin lymphoma. At the time that C. tertiumwas identiﬁed, the ﬁrst patient
was completely asymptomatic, while the second was highly febrile. Both responded biologically and/or
clinically to antibiotherapy. We discuss the epidemiology and pathology of C. tertium in the general and
cancer patient population.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Clostridium tertium is a spore-forming Gram-positive bacillus; it
is anaerobic,1 but aerotolerant.2–8 This bacterium is found in soil,
animal and human gastrointestinal tracts,6,8–10 and the commen-
sal ﬂora of the mouth.2,6 C. tertium is considered to be a weak
pathogen.2–4,6 Its pathogenicity is unclear, but it has been
implicated in severe infections with speciﬁc characteristics. Here,
we report two cases of consecutive bacteremia caused by C.
tertium, and discuss C. tertium pathogenicity and predisposing
factors, epidemiology, and treatment.
2. Case reports
2.1. Case 1
A 51-year-old man was treated in 2006 for M2 acute myeloid
leukemia (AML) without cytogenetic abnormalities. Cytological
and molecular remission was achieved after a classical induction
treatment including cytosine arabinoside and idarubicin, followed
by consolidation with high-dose chemotherapy (cyclophospha-
mide), total body irradiation, and an autologous stem cell* Corresponding author. Current address: Department of Oncology, Cliniques
Universitaires UCL de Mont-Godinne, B-5530 Yvoir, Belgium. Tel.: +32 81 42 38 58;
fax: +32 81 42 38 32.
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doi:10.1016/j.ijid.2010.03.004transplantation. Two years later, there was an AML relapse in
the bone marrow. The patient was admitted to the sterile unit of
the department of hematology and oncology in order to receive a
new course of induction chemotherapy. Upon admission, blood
tests demonstrated pancytopenia: 8.3 g/dl hemoglobin (Hb;
normal range 13–18 g/dl), 0.98  109 leukocytes/l (normal range
4–10.5  109 leukocytes/l), and 10  109 platelets/l (normal range
140–450  109 platelets/l). The patient was completely asymp-
tomatic. There were no signs of infection and he was not taking
antibiotics or other medications. Before beginning the chemother-
apy, a complete bacterial investigation was performed, including
urine, stool, and expectoration analysis, nose and throat swabs, and
three blood cultures. Forty-eight hours later, Gram-positive bacilli
were isolated from all three blood cultures. The patient was on the
third day of cytosine arabinoside andmitoxantrone chemotherapy.
He did not have an elevated temperature and his C-reactive protein
(CRP) level was normal. Broad-spectrum antibiotherapy was
empirically initiated: ceftazidime (6 g/24 h continuous infusion)
and intravenous (IV) teicoplanin (800 mg followed by 400 mg once
a day). Laboratory examination conﬁrmed the presence of C.
tertium in all three blood cultures. Antibiotherapy was adapted
according to the available antibiogram: teicoplanin was stopped
and the patient began taking amoxicillin–clavulanic acid (4 g/
24 h). In vitro, the bacterium was sensitive to penicillin,
amoxicillin–clavulanic acid, erythromycin, and metronidazole,
andwas resistant to clindamycin). Stool analysis and an abdominal
computed tomography (CT) scan did not reveal any abnormalities.
One week after the initiation of antimicrobial therapy the patient’sses. Published by Elsevier Ltd. All rights reserved.
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asymptomatic during the entire hospitalization and no elevated
temperature was ever reported. On day 28, the patient’s bone
marrow had recovered and his blood cell count results had
improved: 1.16  109 leukocytes/l, 190  109 platelets/l, and 7.7 g
hemoglobin/dl. Treatment was halted after 26 and 23 days of
ceftazidime and amoxicillin–clavulanic acid, respectively.
2.2. Case 2
A 23-year-old woman with poor-prognosis diffuse non-
Hodgkin B-cell lymphoma was admitted to the sterile unit of
the department of hematology and oncology for high-dose
chemotherapy treatment. She received the BEAM regimen
(300 mg/m2 BCNU on day 6, 200 mg/m2 VP16 and 200 mg/m2
aracytine from day 5 to day 2, and 140 mg/m2 melphalan on
day1), followed by hematopoietic stem cell (HSC) support on day
0. On the second day of chemotherapy, she presented with a fever
and shivering; empirical antibiotherapy with amoxicillin–clavu-
lanic acid (4 g/24 h) was initiated. The patient had anemia (8.6 g/dl
Hb) and mild leukopenia (2.87  109 leukocytes/l, 99% neutrophils
and 1% lymphocytes), but her platelet count was normal
(140  109 platelets/l). Inﬂammation parameters were normal
and all of the bacterial cultures remained sterile. Three days later,
her temperature was again elevated and CRP levels had
dramatically increased to 20 mg/dl (normal range <1 mg/dl). At
that time, C. tertiumwas isolated from one of three blood cultures.
The patient had no intestinal symptoms and no abdominal CT
imaging was performed. The antibiotherapy was continued
unchanged; her temperature disappeared and inﬂammatory
parameters decreased. HSC were normally infused. Later, an
antibiogram showed that the bacterium was resistant to amoxi-
cillin–clavulanic acid. This antibiotic was stopped after 15 days
(day 9 post-HSC infusion), when fever recurred during neutrope-
nia, and was replaced by IV amikacin (25 mg/kg followed by
15 mg/kg daily) and ceftazidime (6 g/24 h as continuous infusion).
Multiple bacteriologic samples including blood cultures, nose and
throat swabs, and urine and stool analysis remained negative.
Antibiotics were halted on day 14 post-HSC infusion after
hematological recovery and complete disappearance of all signs
of infection. The patient was discharged on day 15. Later
evaluations conﬁrmed she was in complete clinical and radiologi-
cal remission, with no signs of persisting infection.
3. Discussion
C. tertium was ﬁrst described in 1917 by Henry, who isolated it
from the wounds of World War I soldiers.4 It grows best under
anaerobic conditions,4,6 and forms spores only under anaerobic
conditions.4 In contrast with other clostridia, it does not produce
toxins.1,3 When cultured, it is frequently mistaken for a Bacillus
species.6,10 The differential diagnosis is based on the ability of
Bacillus species to form spores in an aerobic environment and the
presence of a catalase in Bacillus species.3–6,11 In addition to its
presence in soil, animal and human guts,6,8–10 and the commensal
ﬂora of the mouth,2,6 C. tertium has also been identiﬁed in
traumatic and surgical wounds.2,3,5,9,11 In wounds, it is usually
considered to be a contaminant, however a case of necrotizing
fasciitis and gangrene has been described.8
Infections with C. tertium are rare and the etiology varies.2
Multiple clinical presentations have been described in the
literature. It has been identiﬁed in premature infants and young
children with enterocolitis,2 and in children and adults with
septicemia, pneumonia with empyema,5–8 spontaneous peritoni-
tis,5–8 colitis,6,8,11 cerebral abcesses,6–8,10,11 abdominal10 and
cutaneous abscesses,7,11,12 meningitis,11 gas gangrene,8 and septicarthritis.3,8,9,12 However, C. tertium is considered to be a weak
pathogen.2–4,6 C. tertium isolates are usually found with other
bacteria.3,6–8,11 Less frequently, it is the only isolate.7,13 Those
patients who died and who had C. tertium in their blood cultures
had severe underlying diseases2,3,5,6,13 that were potentially fatal
in the short term. As a result, the bacterium’s virulence has not yet
been clearly determined.6 Nevertheless, one case of lethal
bacteremia with shock and multiple organ failure was reported
in a woman with colitis, after surgery for ileus.3 C. tertium was the
only pathogen isolated from multiple bacterial samplings. This
case challenges the idea that C. tertium’s pathogenicity is limited to
severely ill or neutropenic patients,6 in whom it can cause often-
fatal intestinal necrosis.7,13 Because C. tertium does not produce
toxins, the pathogenic mechanism of its virulence is unknown.8
Because of the potentially dramatic consequences of infection, it
would be unwise to leave patients with C. tertium untreated, which
further complicates our understanding of its pathogenesis.
Bacteremia and septicemia caused by C. tertium were ﬁrst
described in 1963 by King et al.1 Since then, other cases have been
reported. In 1971, 17 patients with C. tertium-positive blood
cultures were identiﬁed,4 followed by two more in 1975.14 More
recent reports of Clostridium bacteremia have been published;
globally, Clostridium perfringens is the most common isolate. C.
tertium is rare, but is considered to be an emerging pathogen.4,14
The largest series of C. tertium bacteremia was published in 2001
by Miller et al.,2 and comprised 32 patients.
Some common characteristics of C. tertium infection can be
extracted from the literature. Patients may present with elevated
temperature6,7 or gastrointestinal complaints, such as abdominal
pain, diarrhea or constipation, rectal bleeding, and nausea.6–8,11,13
In the series of Miller et al., all of the patients developed a fever.2
However, in some cases, the infection was otherwise perfectly
asymptomatic, and abdominal lesions were found only after
further investigations such as imaging, or even at autopsy.2,7,9
Patient medical histories have frequently revealed blood
diseases such as leukemia or marrow aplasia;4,7,12 inﬂammatory
bowel diseases such as Crohn’s disease or ulcerative colitis;6,12
hepatic failure;6,8 abdominal surgeries such as gastrostomy;2–4,6,12
or immune disorders, such as systemic lupus, that were treated
with high doses of corticosteroids.3 Bacteremia preferentially
affects patients with immune deﬁciencies, either systemic or
localized. For example, in the gastrointestinal tract, mucosal
breaches allow bacterial translocation.2–4,8,11 Moreover, chemo-
therapy can lead to inﬂammation and abrasion of the intestinal
mucosa.3,9,11 This may partially explain the increased susceptibili-
ty to infection of patients with hematological diseases who are
undergoing chemotherapy.
A large number of the patients described in the literature were
neutropenic when bacteremia was diagnosed,2,3,6–9,11–13 but there
are exceptions.2,6 Typically, the few patients who developed
bacteremia without neutropenia presented with gastrointestinal
symptoms.6,10 Interestingly, most patients with C. tertium bacter-
emia were neutropenic without a deﬁned source of infection.2
Regarding predisposing medications, third-generation cephalos-
porins2–4,8,12 and aminoglycosides appear to be risk factors for the
development of C. tertium infections; the bacterium is resistant to
these antibiotics, and is thus selected for.6,9,11 Administration of
broad-spectrum antibiotics also facilitates the growth of resistant
bacteria.7
No prophylaxis is recommended to prevent C. tertium growth
due to the low incidence of infection and the uncertainty regarding
its pathogenicity. C. tertium is resistant to beta-lactams and
clindamycin,2–5,9,11 and sensitive to quinolones,2,3,7 imipe-
nem,3,6,9,11,12 vancomycin,2,3,6,7,11,12 and trimethoprim–sulfa-
methoxazole.2,3,7,9 It can be either sensitive5,6,11,12 or
resistant2,5–7,9 to metronidazole. Some authors have observed
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antibiotics is generally initiated, but there are no guidelines.1,4,6,7
The duration of antibiotherapy is rarely mentioned in the
literature, but appears to range from 15 to 27 days.4,10 In our
ﬁrst case report, the patient received intravenous antibiotherapy
for the entire duration of marrow aplasia, from the time that
bacteremia was ﬁrst noted (24 days in total). Interestingly, in
contrast with the literature, C. tertium in our patient was sensitive
to beta-lactams. For our second patient, the antibiogram matched
the data in the literature; even so, amoxicillin–clavulanic acid was
administered successfully, although the bacteriumwas resistant in
vitro. In this case, antibiotherapywas continued for nearly 21 days.
Some authors have doubts about the clinical importance of the
identiﬁcation of C. tertium.1,4,6,11 However, in the series of Miller
et al., four patients died within a week after C. tertium was
identiﬁed.2 In the two cases that we report here, we considered the
possibility of culture contamination because of the atypical clinical
presentation (the ﬁrst patient was completely asymptomatic) and
because the bacterium was isolated from only one of three blood
cultures from the second patient. In the latter case, the infection
clinically and bacteriologically improved despite in vitro evidence
of inadequate antibiotherapy. C. tertium is aerotolerant and present
in the commensal ﬂora of the mouth, increasing the likelihood of
contamination. However, both patients were at risk (because of
hematological malignancies, leukopenia, and chemotherapy) for C.
tertium bacteremia, and were treated in the same sterile unit
within a short period of time (less than three months); thus,
contamination seems unlikely.
In conclusion, we report two cases of C. tertium bacteremia
observed in the sterile unit of our department of hematology and
oncology within a short period of time. Both patients were
susceptible to C. tertium infection because of their hematological
disease and neutropenia. In the ﬁrst patient, who was completely
asymptomatic, the bacteremia was discovered during routine
bacteriologic sampling before starting chemotherapy. The symp-toms of the second patient improved despite the patient receiving
an antibiotic to which the bacterium was resistant in vitro. C.
tertium’s pathogenicity appears to be low, and it is not entirely
clear if C. tertium is a true pathogen or merely a bystander
contaminant. In addition, the appropriate duration of antibiother-
apy is still a matter of debate.
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